1. Introduction
===============

Lung cancer is the leading cause of cancer-related mortality both in China and worldwide, and non-small cell lung cancer (NSCLC) comprises the majority of all lung cancer cases.^\[[@R1],[@R2]\]^ More than half of the NSCLC patients are diagnosed at advanced stage, and the prognosis is poor. The median survival time was about 12 months before the era of target therapy.[@R3] During the past decades, the development of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) has significantly improved the prognosis of the patients harboring EGFR mutation. EGFR-TKIs now act as the standard first-line treatment of the EGFR-mutant advanced NSCLC patients, with a median response rate of about 60%, and median progression free survival (PFS) 10 months.[@R4] However, most of the patients will develop drug resistance and resulted in treatment failure, which is the major challenge of clinical work. Therefore, exploring prognostic factors that can predict target therapy efficacy is important.

Increasing evidence has demonstrated that host immune-inflammation status plays an important role in the prognosis of the patients. There have been several immune-inflammation based indicators, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) which can predict survival in many solid tumors.^\[[@R5],[@R6],[@R7],[@R8],[@R9]\]^ The systemic immune-inflammation index (SII) is also a simple and inexpensive marker which has been reported to be predictive in the prognosis in colorectal cancer,[@R10] NSCLC,[@R11] ovarian cancer,[@R12] pancreatic cancer,[@R13] and hepatocellular carcinoma.[@R14] However, the prognostic value of SII in EGFR-Mutant advanced NSCLC patients treated with EGFR-TKI has been rarely reported.

In the present study, a cohort of 203 EGFR-mutant advanced lung adenocarcinoma patients were retrospectively analyzed to evaluate the clinical significance and prognostic value of NLR, PLR, and SII in NSCLC patients receiving EGFR-TKI treatment.

2. Patients and methods
=======================

2.1. Patients selection
-----------------------

We retrospectively reviewed the records of newly diagnosed stage IV lung adenocarcinoma patients between Jan 2013 and Nov 2018 at the Second Xiangya Hospital in Changsha, China. The patients who met the following inclusion criteria were included:

1.  pathologically diagnosed as lung adenocarcinoma,

2.  harboring EGFR active mutation,

3.  using first generation EGFR-TKI (gefitinib, erlotinib, or icotinib) as the first-line treatment,

4.  with complete record of blood test results within 1 week prior to the initiation of EGFR-TKI treatment and follow-up record.

Patients who met the following exclusion criteria were excluded:

1.  history of other malignant tumors and chronic inflammatory diseases,

2.  with recent steroid therapy,

3.  with recent clinical evidence of acute infection or inflammation.

Consequently, 203 patients were enrolled in the present study. The study was approved by the ethics committee of the Second Xiangya Hospital, Central South University.

2.2. Data collection
--------------------

Patient characteristics including gender, age, smoking history, brain metastasis status, ECOG score, EGFR mutation status, and full blood counts were obtained from the electronic medical record system of the Second Xiangya Hospital. The SII, NLR, and PLR were calculated as follows: SII = platelet counts × neutrophil counts / lymphocyte counts, NLR = neutrophil counts / lymphocyte counts, PLR = platelet counts / lymphocyte counts. The last follow-up occurred in December 31, 2018. The overall survival (OS) was calculated from the date of diagnosis to the date of death for any reason or to the last date of follow-up. The progression-free survival (PFS) was calculated from the date of diagnosis to the date of disease progression based on response evaluation criteria in solid tumors (RECIST) 1.1, or death.

2.3. Statistical methods
------------------------

The relationship between SII, NLR, and PLR and clinicopathological factors were analyzed using the chi-square test. Receiver operating characteristic (ROC) curves were used to calculate the optimal cut-off value for SII, NLR, and PLR. Survival analysis was performed using Kaplan--Meier method. The differences between the survival curves were compared by log-rank test. The multivariate Cox hazard regression analysis was performed on the factors that were shown to be significant on univariate analysis. All tests were 2-sided and *P* values less than .05 were considered significant. The SPSS software 20.0 was used.

3. Results
==========

3.1. Patient characteristics
----------------------------

The patient characteristics are shown in Table [1](#T1){ref-type="table"}. A total of 203 advanced EGFR-mutant lung adenocarcinoma patients were included, among which 89 (43.8%) were male and 114 (56.2%) were female. The median age was 59 years (range: 28--79 years). Sixty patients (29.6%) had a smoking history. The majority of patients had an ECOG score of 0 to 1 (168, 82.8%). In all the patients, 89 (43.8%) patients had the exon 21 L858R mutation, 108 (53.2%) the exon 19 deletion mutation, and 6 (3%) other rare mutations. There are 25 (12.3%) patients who had brain metastasis, and 5 patients received whole brain radiation therapy (WBRT) concurrent with TKI.

###### 

Clinicopathological characteristics of patients.
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3.2. Cut-off value of SII, NLR, PLR, and their association with clinicopathological characteristics
---------------------------------------------------------------------------------------------------

The median values for SII, NLR, and PLR of all these patients were 796.85 (range: 167.49--4021.94), 3.26 (range: 0.83--12.74) and 173.55 (range: 55.30--847.37). The optimal cut-off values of SII, NLR, and PLR were determined by ROC analysis. As shown in Figure [1](#F1){ref-type="fig"}A, the area under the curve (AUC) for PFS were 0.653, 0.625, and 0.644. The optimal values of SII, NLR, and PLR for the prediction of PFS were 1066.935, 4.40, and 182.595. As shown in Figure [1](#F1){ref-type="fig"}B, the AUC for OS were 0.593, 0.561, and 0.586. The optimal values of SII, NLR, and PLR for the prediction of PFS were 1343.665, 4.60, and 182.595.

![A Receiver operating characteristic curve analysis for optimal cut-off value of NLR, PLR, and SII for PFS. B. Receiver operating characteristic curve analysis for optimal cut-off value of NLR, PLR, and SII for OS. NLR = Neutrophil to Lymphocyte Ratio, OS = Overall Survival, PFS = Progression Free Survival, PLR = Platelet to Lymphocyte Ratio, SII = Systemic Immune-inflammation Index.](medi-98-e16875-g002){#F1}

The relationship between SII, NLR, and PLR and patient clinicopathological characteristics is shown in Table [2](#T2){ref-type="table"}. Patients with high SII, NLR, and PLR were more likely to have worse Eastern Cooperative Oncology Group performance status (ECOG PS) (*P* = .002, 0.006, 0.001, respectively). However, SII, NLR, and PLR did not show any significant correlation with age, gender, smoking status, brain metastasis, and EGFR mutation status using the cut-off value mentioned above.
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Clinicopathological characteristics according to SII, NLR, and PLR.
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3.3. Univariate and multivariate Cox regression analysis for PFS and OS
-----------------------------------------------------------------------

On univariate cox regression analyses, NLR (*P* \< .001), PLR (*P* = .002), and SII (*P* \< .001) were significantly associated with PFS, and brain metastasis is of boarder significance (*P* = .052). NLR (*P* \< .001) and SII (*P* \< .001) were significantly associated with OS, while brain metastasis (*P* = .09) and PLR (*P* = .08) were of boarder significance (Table [3](#T3){ref-type="table"}, Figs. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). All other clinicopathological characteristics were not statistically significant. In the multivariate Cox regression analysis, as shown in Table [4](#T4){ref-type="table"}, NLR (HR 1.736; 95% CI 1.020--2.954; *P* = .03), PLR (HR 1.823; 95% CI 1.059--3.137; *P* = .04) and SII (HR 2.577; 95% CI 1.677--3.958; *P* \< .001) were independent prognostic factors for PFS. Only SII (HR 2.802; 95% CI 1.659--4.733; *P* \< .001) was independent prognostic factors for OS.
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Univariate analysis of potential factors associated with PFS and OS.
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![Kaplan--Meier curves of PFS according to NLR (A), PLR (B), and SII (C). NLR = Neutrophil to Lymphocyte Ratio, PLR = Platelet to Lymphocyte Ratio, SII = systemic immune-inflammation index.](medi-98-e16875-g005){#F2}

![Kaplan--Meier curves of OS according to NLR (A), PLR (B), and SII (C). NLR = Neutrophil to Lymphocyte Ratio, PLR = Platelet to Lymphocyte Ratio, SII = systemic immune-inflammation index.](medi-98-e16875-g006){#F3}
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Multivariable Cox regression analyses for PFS and OS.
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4. Discussion
=============

In the present study, we evaluated the prognostic value of blood-based immune-inflammation factors, SII, NLR, and PLR, in EGFR-mutant advanced lung adenocarcinoma patient treating with first-line EGFR-TKIs. We found that patients with SII ≥ 1066.935, NLR ≥ 4.40, and PLR ≥ 182.595 were more likely to have worse ECOG PS scores. Patients with a smoking history were more likely to have higher PLR. Patients with higher NLR were more likely to have brain metastasis. Further, the pretreatment SII, NLR, and PLR were independent prognostic factors for PFS, while only SII was the independent prognostic factor for OS. Compared with NLR and PLR, SII had higher prognostic ability.

Inflammation is a hallmark of cancer, which can promote tumorigenesis and progression of cancer.[@R15] Tumor cells could secret proinflammatory factors, and systemic inflammation could in return promote tumor cell proliferation, promote angiogenesis, and inhibit host anti-tumor immune response.[@R16] It has been reported that about 30% to 50% of advanced cancer patients were with evidence of systemic inflammation, who were more likely to have a worse prognosis.[@R17] Inflammatory cells, including neutrophils, lymphocytes and platelets, and other factors, such as C-reactive protein (CRP) have been reported to be associated with prognosis in various cancers. Neutrophil is an indicator of acute and chronic inflammation which can promote tumor progression and inhibit anti-tumor immunity.^\[[@R18],[@R19]\]^ Lymphocyte, especially T lymphocyte, plays an important role in host anti-tumor immunity,[@R20] and treatment related lymphopenia is reported to be associated with poor prognosis.[@R21] Thrombocytosis is a paraneoplastic syndrome which is widely accepted as an adverse prognosis factor of cancer patients.[@R22] However, one of the major challenges in this area is that there is still lack of consensus of the indicators of systemic inflammation. A series of indicators, based on those factors mentioned above have been established and reported to be associated with prognosis of cancer patients, including NLR,[@R5] PLR,[@R7] and Glasgow prognostic score (GPS).^\[[@R23],[@R24]\]^ SII is a comparatively new indicator based on the account of three types of peripheral immune cells, and is suggested to better reflect the host immune and inflammation status compared with NLR or PLR. Previous studies have demonstrated prognostic value of SII and its superiority over NLR and PLR in various cancers.^\[[@R25],[@R26],[@R27]\]^

The prognostic value of SII in NSCLC has also been reported. Tomita et al[@R28] conducted a retrospective analysis in NSCLC patients after curative resection and found that SII was an independent predictive indicator for cancer-specific survival, and patients with SII \< 471.2 had a significant better 5-year OS (83.61% vs 60.39%, *P* \< .001). Another research in stage III NSCLC patients reported that patients with SII \< 660 had a better OS (HR 2.105; 95%CI: 1.481--2.741; *P* \< .001), and SII is superior to NLP and PLR in terms of prognostic ability.[@R29] For advanced stage patient, Guo et al[@R11] reported that SII was also a prognosis factor. Patients with SII \< 521 had a better PFS (HR 5.009; 95%CI: 1.996--12.570; *P* = .001) and OS (HR 2.824; 95% CI: 1.285--6.207; *P* = .01). In another research on lung adenocarcinoma with brain metastasis, Li et al[@R30] reported that SII ≤ 1218.81 was associated with prolonged OS (HR 2.179; 95% CI: 1.616--2.940; *P* \< .001).

The current principle of cancer treatment is multimodality comprehensive treatment, including surgery, chemotherapy, radiation therapy, target therapy, and immunotherapy. Different modality has different mechanism, resistance mechanism, and different effect on host immune and inflammation status. Previous studies mainly focused on the prognostic role of immune and inflammation indicators in NSCLC patients receiving resection, chemotherapy and radiation therapy. The report on the prognostic role of those indicators in NSCLC patients receiving EGFR-TKI is rare. Aguiar-Bujanda et al[@R31] reported that NLR is a prognostic factor in European patients with EGFR-Mutant NSCLC Treated with TKIs. In a subgroup analysis of Li\'s research, they revealed that SII was of boarder significance in predicting the survival of EGFR-mutant lung adenocarcinoma patients with brain metastasis, with a *P* = .08. In the present study, we found that SII, NLR, and PLR were prognostic factors for PFS, and only SII was the prognostic factors for OS. Our study is partially consistence with previous study. Since there were only 25 patients with brain metastasis were included, and the cut-off value was 1066.935 for PFS, and 1343.665 for OS in our research, the inconsistency may result from different inclusion criteria and different cut-off values.

Besides effecting immune status, systemic inflammation also induces metabolism impairment and results in mal-nutrition, including cancer related cachexia, which also contribute to morbidity and mortality in cancer.[@R32] Cachexia is a complication of cancer whose major manifestation is loss of muscle and fat mass.[@R33] It is caused by pro-inflammatory cytokines, including IL-6 and related cytokines, and JAK/STAT and PI3K/Akt/mTOR pathway were demonstrated to be involved in the pathogenesis of cachexia.^\[[@R32],[@R34]\]^ Cachexia is prevalent in advanced stage cancer patients, and is correlated with shorter survival and worse quality-of-life.[@R35] Therefore, exploring the pathogenesis of systemic inflammation and mal-nutrition provides new insights in interventions to improve the prognosis of cancer patients. Some basic researches have demonstrated that reversal of cancer cachexia could prolong survival in rats.[@R36] There is early clinical trial showing that agent targeting JAK2 may be effective in advanced nonsquamous NSCLC with systemic inflammation.[@R37] However, effective interventions and agents are still lacking, which worth further research.

Although our research suggested the prognostic value of SII in EGFR-mutant lung adenocarcinoma patients treated with first-line EGFR-TKI, there are some limitations in our research. First, this was a single center retrospective study with a comparably small sample size. The imbalance between groups may bring some bias to the results. Such as, the number of patients with brain metastasis and ECOG PS score of \>2 was small. Second, the cut-off values calculated based-on ROC were different from previous studies, which makes it very hard to compare our results with others. Due to the retrospective nature of most of the studies in this area, multicenter prospective research with larger sample size is still needed to further verify the prognostic value of SII in this group of patients.

In conclusion, the present study showed that the SII, a blood-based immune inflammation index is independently associated with PFS and OS in EGFR-Mutant lung adenocarcinoma patients treated with first-line EGFR-TKIs. It may be an easy-to-derive prognostic factor for these patients which worth further research.
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